Evidence map›Paper›PMID 41816616›Full record

ArticleChemical science2026

Stearic acid-modified PSMA-targeting peptide-drug conjugate for long-acting prostate cancer therapy.

Ziwen Qiu, Xiaorui Zheng, Shoumei Pan, Yingtao Zhong, Xiayun Chen, Xuejun Wen, Xin Chen, Shiying Li, Hong Cheng, Xiaoyuan Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ziwen QiuDepartment of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University Guangzhou 510280 China chen_xin1020@163.com.
Xiaorui ZhengBiomaterials Research Center, School of Biomedical Engineering, Southern Medical University Guangzhou 510515 China chengh@smu.edu.cn.
Shoumei PanBiomaterials Research Center, School of Biomedical Engineering, Southern Medical University Guangzhou 510515 China chengh@smu.edu.cn.
Yingtao ZhongBiomaterials Research Center, School of Biomedical Engineering, Southern Medical University Guangzhou 510515 China chengh@smu.edu.cn.
Xiayun ChenGuangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA, State Key Laboratory of Respiratory Disease, The School of Pharmaceutical Sciences, Guangzhou Medical University Guangzhou 511436 China lisy-sci@gzhmu.edu.cn.
Xuejun WenDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore 119074 Singapore.
Xin ChenDepartment of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University Guangzhou 510280 China chen_xin1020@163.com.
Shiying LiDepartment of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University Guangzhou 510280 China chen_xin1020@163.com.ORCID https://orcid.org/0000-0003-0666-7634
Hong ChengBiomaterials Research Center, School of Biomedical Engineering, Southern Medical University Guangzhou 510515 China chengh@smu.edu.cn.ORCID https://orcid.org/0000-0002-3560-4432
Xiaoyuan ChenShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences Jinan 250117 China chen9647@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA)-targeting peptide-drug conjugates (PDCs) offer promise for the treatment of PSMA-positive prostate cancer, but their applications are limited by rapid clearance, poor pharmacokinetics, and low efficacy. Herein, we design a series of PDCs incorporating rational functional moieties, including a Glu-Ureido-Lys PSMA-targeting ligand, the cytotoxic payload monomethyl auristatin E (MMAE), and a cathepsin B-cleavable Val-Cit linker, combined with structural modifications such as free amine exposure, acetylation, stearic acid acylation, or

Identifiers

PMID41816616
PMCPMC12973224

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.